New hope for rare stomach cancer: drug cocktail targets tough cases
NCT ID NCT07289997
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of four drugs (iparomlimab, tuvonralimab, apatinib, and irinotecan) in 39 adults with advanced AFP-producing stomach or gastroesophageal junction cancer that has worsened after initial immunotherapy and chemotherapy. The goal is to see if this new mix can shrink tumors or slow the disease. Participants receive treatment until the cancer progresses, side effects become too severe, or up to two years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AFP GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hebei Medical University Fourth Hospital
RECRUITINGShijiazhuang, Hebei, 050000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an AI coach and simple exercises help cancer patients fight frailty?
- Triple therapy takes on rare, aggressive kidney cancer
- Bladder cancer drug delivered directly: a new hope for BCG failures
- Immunotherapy combo may boost rectal cancer treatment
- New cocktail aims to make immunotherapy work for common colorectal cancer
- Modified herpes virus joins forces with immunotherapy to attack head and neck tumors